Spero Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	40.55	47.98	103.78	53.51	18.26	9.33
Revenue Growth (YoY)	-61.91%	-53.77%	93.95%	193.10%	95.67%	-48.59%
Cost of Revenue	61.71	96.76	51.44	47.59	64.53	67
Gross Profit	-21.16	-48.78	52.34	5.92	-46.27	-57.67
Selling, General & Admin	23.93	23.7	25.55	36.48	41.7	21.44
Operating Expenses	23.93	23.7	25.55	36.48	41.7	21.44
Operating Income	-45.09	-72.48	26.79	-30.57	-87.97	-79.11
Interest Expense	-	-	-	-2.61	-1.94	-
Interest & Investment Income	3.16	4.74	3.94	1.11	0.35	0.4
Currency Exchange Gain (Loss)	-	-	-	-	-	0.43
Other Non Operating Income (Expenses)	0.11	0.06	-0.01	0.86	-0.19	-
EBT Excluding Unusual Items	-41.82	-67.69	30.71	-31.2	-89.76	-78.28
Merger & Restructuring Charges	-1.14	-0.88	-	-11.63	-	-
Asset Writedown	-0.59	-	-5.31	-	-	-
Other Unusual Items	-	-	-	-3.58	-	-
Pretax Income	-43.55	-68.57	25.4	-46.42	-89.76	-78.28
Income Tax Expense	0.29	-	2.6	-	-	-
Earnings From Continuing Operations	-43.84	-68.57	22.81	-46.42	-89.76	-78.28
Net Income	-43.84	-68.57	22.81	-46.42	-89.76	-78.28
Preferred Dividends & Other Adjustments	-	-	-	-	-	0.55
Net Income to Common	-43.84	-68.57	22.81	-46.42	-89.76	-78.83
Shares Outstanding (Basic)	56	54	53	38	31	22
Shares Outstanding (Diluted)	56	54	53	38	31	22
Shares Change (YoY)	2.96%	1.98%	40.98%	21.65%	38.01%	23.27%
EPS (Basic)	-0.79	-1.27	0.43	-1.23	-2.91	-3.52
EPS (Diluted)	-0.79	-1.27	0.43	-1.23	-2.91	-3.52
Free Cash Flow	-27.67	-23.44	-33	-7.73	-64.35	-86.03
Free Cash Flow Per Share	-0.50	-0.43	-0.62	-0.21	-2.08	-3.84
Gross Margin	-52.19%	-101.67%	50.43%	11.06%	-253.45%	-
Operating Margin	-111.21%	-151.08%	25.81%	-57.13%	-481.87%	-847.94%
Profit Margin	-108.11%	-142.91%	21.98%	-86.74%	-491.65%	-844.90%
Free Cash Flow Margin	-68.25%	-48.86%	-31.79%	-14.45%	-352.47%	-922.07%
EBITDA	-45.09	-72.48	27.15	-29.7	-87.33	-78.35
EBITDA Margin	-111.20%	-151.08%	26.16%	-55.50%	-	-
D&A For EBITDA	0	0	0.37	0.87	0.65	0.76
EBIT	-45.09	-72.48	26.79	-30.57	-87.97	-79.11
EBIT Margin	-111.21%	-151.08%	25.81%	-57.13%	-	-
Effective Tax Rate	-	-	10.23%	-	-	-
Revenue as Reported	40.55	47.98	103.78	53.51	18.26	9.33

Source: S&P Global Market Intelligence. Standard template. Financial Sources.